A Phase 4 interventional study of Alpha1-proteinase inhibitor and Placebo in Alpha1-proteinase Inhibitor Deficiency and Emphysema, sponsored by CSL Behring. Completed at 28 sites in 13 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-01-19.
Sponsored by CSL Behring (part of CSL Limited) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency — 2 open to participants now, 2 under way, 1 of them phase 3. alpha 1-Antitrypsin · alpha 1-Antitrypsin Deficiency.
Among the 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency, this one is the 4th largest by enrollment, is one of 4 that started in 2006, is one of 6 in phase 4, and was the 2nd registered.
142 studies on the registry are indexed under alpha 1-Antitrypsin Deficiency; 32 are open to participants now.
Browse alpha 1-Antitrypsin Deficiency studies →2 of the 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency are open now, in 12 countries. Recruiting first, the newest first:
CSL Behring · Sites in Denmark
Ages 18–65
Grifols Therapeutics LLC · Sites in United States, Australia, Canada and 9 more countries
Ages 20–72
By country, each count listing its studies:
alpha 1-Antitrypsin: first FDA approval 1987 (prolastin,prolastin-c,prolastin-c liquid), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 24 alpha 1-Antitrypsin Deficiency studies recruiting now, 11 (46%) set no upper age limit and 10 (42%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 10 · Phase 3 7 · Phase 4 6
First in 2003; this study’s year is marked. 4 started in 2006.
This study's enrollment of 180 is above the median of 33 across 86 interventional studies indexed under alpha 1-Antitrypsin Deficiency.
Median enrollment 30 across the 25 interventional studies. Of the 19 that completed or were terminated, 16 (84%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 25 have an industry lead sponsor. The 10 most frequent:
This study is registered under CSL Behring, one of the names counted as CSL Limited. Under that name alone:
CSL Behring is the lead sponsor of 145 studies on the registry; 17 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 17 (71%) have results posted.
CSL Limited has 4 studies filed under alpha 1-Antitrypsin Deficiency — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized, placebo-controlled, double-blind, multicenter phase III/IV study to compare the efficacy and safety of Zemaira® with placebo in subjects with emphysema due to alpha1-proteinase inhibitor deficiency. The effect of Zemaira® on the progression of emphysema will be assessed by the decline of lung density, measured by computed tomography (CT).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Alpha1-proteinase inhibitor
Other: Placebo
60 mg/kg body weight/week intravenous
Also known as: Zemaira®
Lyophilized preparation: 60 mg/kg body weight/week intravenous
Annual Rate of Change in Lung Density
As measured by centralized, standardized computer tomographic (CT) lung densitometry. CT scans were acquired at 2 inspiration states: TLC (ie, full inspiration) and FRC (ie, full expiration). Results were adjusted for total lung volume and are presented as point estimates for the average rate of decline in each treatment group.
Time frame: Over a 2-year period
Annual Rate of Pulmonary Exacerbations
Primary diagnostic criteria for exacerbations were increased dyspnea, increased sputum volume, and increased sputum purulence. Supporting diagnostic criteria were upper respiratory tract infection, fever without other apparent cause, increased wheezing, and increased cough. For diagnosis, participants had to meet 2 of the 3 primary criteria or 1 primary criterion and 1 supporting criterion. The annual rate was based on the total number of exacerbations and the total number of participant study days for all participants in the specified analysis population and adjusted to 365.25 days.
Time frame: Over a 2-year period
Percent Change in FEV1
Percent change from baseline to Month 24.
Time frame: From baseline to 2 years
Time to First Pulmonary Exacerbation
Primary diagnostic criteria for exacerbations were increased dyspnea, increased sputum volume, and increased sputum purulence. Supporting diagnostic criteria were upper respiratory tract infection, fever without other apparent cause, increased wheezing, and increased cough. For diagnosis, participants had to meet 2 of the 3 primary criteria or 1 primary criterion and 1 supporting criterion.
Time frame: Over a 2-year period
Change in Lung Density
Change from baseline to Month 24 as measured by centralized, standardized CT lung densitometry. CT scans were acquired at 2 inspiration states: TLC (ie, full inspiration) and FRC (ie, full expiration). Results were adjusted for total lung volume.
Time frame: From baseline to 2 years
Change in Exercise Capacity
Exercise capacity was measured as distance walked, using the incremental shuttle walk test. Change from baseline to end of treatment (2 years) in exercise capacity was analysed using an analysis of covariance (ANCOVA).
Time frame: From baseline to 2 years
Change in Patient-reported Symptoms
Patient-reported symptoms were measured using the symptoms score component of the St George's Respiratory Questionnaire (SGRQ). SGRQ scores range from 0 to 100, with higher scores indicating more limitations and negative values for change indicating improvement. Change from baseline to end of treatment (2 years) in SGRQ was analysed using an ANCOVA.
Time frame: From baseline to 2 years
Frequency and Intensity of Adverse Events (AEs)
Number of participants with at least one AE, and the number of participants with mild, moderate or severe AEs. AE intensity was defined as mild (does not interfere with routine activities), moderate (interferes with routine activities), or severe (impossible to perform routine activities).
Time frame: Over a 2-year period
Percent Change in Percent Predicted FEV1
Percent change from baseline to Month 24.
Time frame: From baseline to 2 years
Percent Change in FEV1 Divided by Forced Vital Capacity
Percent change from baseline to Month 24.
Time frame: From baseline to 2 years
Percent Change in DLCO
Percent change from baseline to Month 24.
Time frame: From baseline to 2 years
Duration of Pulmonary Exacerbations Relative to Treatment Duration
Defined as the percentage of total treatment duration across participants for 1) exacerbations overall, 2) antibiotic treatment for exacerbations, and 3) hospitalization for exacerbations. Primary diagnostic criteria for exacerbations were increased dyspnea, increased sputum volume, and increased sputum purulence. Supporting diagnostic criteria were upper respiratory tract infection, fever without other apparent cause, increased wheezing, and increased cough. For diagnosis, participants had to meet 2 of the 3 primary criteria or 1 primary criterion and 1 supporting criterion.
Time frame: Over a 2-year period
Severity of Pulmonary Exacerbations
Defined as the number of participants requiring 1) antibiotic treatment for exacerbations, and 2) hospitalization for exacerbations. Primary diagnostic criteria for exacerbations were increased dyspnea, increased sputum volume, and increased sputum purulence. Supporting diagnostic criteria were upper respiratory tract infection, fever without other apparent cause, increased wheezing, and increased cough. For diagnosis, participants had to meet 2 of the 3 primary criteria or 1 primary criterion and 1 supporting criterion. Antibiotic treatment usage was reported by quarterly interval.
Time frame: Over a 2-year period
Baseline Lung Density at Total Lung Capacity (TLC) and Forced Residual Capacity (FRC)
Time frame: Baseline
This multicenter, multinational study enrolled participants at 28 study centers in Europe, North America, and Australia.
| Milestone | Zemaira® | Placebo |
|---|---|---|
| Started | 93 | 87 |
| Completed | 84 | 69 |
| Not completed | 9 | 18 |
| Withdrew: Death | 1 | 3 |
| Withdrew: Adverse event | 1 | 4 |
| Withdrew: Withdrawal by subject | 5 | 7 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Suspicion of pulmonary cancer | 0 | 1 |
| Withdrew: Lung transplantation | 1 | 1 |
| Withdrew: Missing reason | 1 | 0 |
| Withdrew: Not interested in being participant | 0 | 1 |
As measured by centralized, standardized computer tomographic (CT) lung densitometry. CT scans were acquired at 2 inspiration states: TLC (ie, full inspiration) and FRC (ie, full expiration). Results were adjusted for total lung volume and are presented as point estimates for the average rate of decline in each treatment group.
| g/L per year | Zemaira® | Placebo |
|---|---|---|
| TLC + FRC combined | -1.50 ± 0.22 | -2.12 ± 0.24 |
| TLC | -1.45 ± 0.23 | -2.19 ± 0.25 |
| FRC | -1.55 ± 0.24 | -2.02 ± 0.26 |
Primary diagnostic criteria for exacerbations were increased dyspnea, increased sputum volume, and increased sputum purulence. Supporting diagnostic criteria were upper respiratory tract infection, fever without other apparent cause, increased wheezing, and increased cough. For diagnosis, participants had to meet 2 of the 3 primary criteria or 1 primary criterion and 1 supporting criterion. The annual rate was based on the total number of exacerbations and the total number of participant study days for all participants in the specified analysis population and adjusted to 365.25 days.
| exacerbations per participant year | Zemaira® | Placebo |
|---|---|---|
| Annual Rate of Pulmonary Exacerbations | 1.70 (1.51 to 1.89) | 1.42 (1.23 to 1.61) |
Percent change from baseline to Month 24.
| percent change | Zemaira® | Placebo |
|---|---|---|
| Percent Change in FEV1 | -4.29 ± 1.26 | -2.06 ± 1.30 |
Primary diagnostic criteria for exacerbations were increased dyspnea, increased sputum volume, and increased sputum purulence. Supporting diagnostic criteria were upper respiratory tract infection, fever without other apparent cause, increased wheezing, and increased cough. For diagnosis, participants had to meet 2 of the 3 primary criteria or 1 primary criterion and 1 supporting criterion.
| Years | Zemaira® | Placebo |
|---|---|---|
| Time to First Pulmonary Exacerbation | 0.60 (0.33 to 1.11) | 0.73 (0.46 to 1.17) |
Change from baseline to Month 24 as measured by centralized, standardized CT lung densitometry. CT scans were acquired at 2 inspiration states: TLC (ie, full inspiration) and FRC (ie, full expiration). Results were adjusted for total lung volume.
| g/L | Zemaira® | Placebo |
|---|---|---|
| TLC + FRC combined | -2.33 ± 0.45 | -3.37 ± 0.50 |
| TLC (N=66 for placebo) | -2.22 ± 0.47 | -3.54 ± 0.52 |
| FRC | -2.44 ± 0.50 | -3.33 ± 0.56 |
Exercise capacity was measured as distance walked, using the incremental shuttle walk test. Change from baseline to end of treatment (2 years) in exercise capacity was analysed using an analysis of covariance (ANCOVA).
| metre | Zemaira® | Placebo |
|---|---|---|
| Change in Exercise Capacity | 1.77 ± 13.0 | 14.86 ± 13.5 |
Patient-reported symptoms were measured using the symptoms score component of the St George's Respiratory Questionnaire (SGRQ). SGRQ scores range from 0 to 100, with higher scores indicating more limitations and negative values for change indicating improvement. Change from baseline to end of treatment (2 years) in SGRQ was analysed using an ANCOVA.
| units on a scale | Zemaira® | Placebo |
|---|---|---|
| Change in Patient-reported Symptoms | -1.19 ± 1.79 | -0.09 ± 1.93 |
Number of participants with at least one AE, and the number of participants with mild, moderate or severe AEs. AE intensity was defined as mild (does not interfere with routine activities), moderate (interferes with routine activities), or severe (impossible to perform routine activities).
| participants | Zemaira® | Placebo |
|---|---|---|
| At least 1 AE | 92 | 86 |
| Mild AEs | 13 | 16 |
| Moderate AEs | 54 | 43 |
| Severe AEs | 25 | 27 |
Percent change from baseline to Month 24.
| percent change | Zemaira® | Placebo |
|---|---|---|
| Percent Change in Percent Predicted FEV1 | -4.16 ± 1.27 | -1.90 ± 1.31 |
Percent change from baseline to Month 24.
| percent change | Zemaira® | Placebo |
|---|---|---|
| Percent Change in FEV1 Divided by Forced Vital Capacity | -2.68 ± 1.36 | 1.56 ± 1.40 |
Percent change from baseline to Month 24.
| percent change | Zemaira® | Placebo |
|---|---|---|
| Percent Change in DLCO | -3.16 ± 1.96 | -1.85 ± 2.03 |
Defined as the percentage of total treatment duration across participants for 1) exacerbations overall, 2) antibiotic treatment for exacerbations, and 3) hospitalization for exacerbations. Primary diagnostic criteria for exacerbations were increased dyspnea, increased sputum volume, and increased sputum purulence. Supporting diagnostic criteria were upper respiratory tract infection, fever without other apparent cause, increased wheezing, and increased cough. For diagnosis, participants had to meet 2 of the 3 primary criteria or 1 primary criterion and 1 supporting criterion.
| percentage of total treatment duration | Zemaira® | Placebo |
|---|---|---|
| Exacerbations (n = 68, 59) | 77.2 ± 98.8 | 58.9 ± 109.1 |
| Antibiotic treatment (n = 59, 52) | 6.32 ± 6.75 | 5.55 ± 6.80 |
| Hospitalization (n = 19, 16) | 6.22 ± 8.79 | 2.16 ± 1.67 |
Defined as the number of participants requiring 1) antibiotic treatment for exacerbations, and 2) hospitalization for exacerbations. Primary diagnostic criteria for exacerbations were increased dyspnea, increased sputum volume, and increased sputum purulence. Supporting diagnostic criteria were upper respiratory tract infection, fever without other apparent cause, increased wheezing, and increased cough. For diagnosis, participants had to meet 2 of the 3 primary criteria or 1 primary criterion and 1 supporting criterion. Antibiotic treatment usage was reported by quarterly interval.
| participants | Zemaira® | Placebo |
|---|---|---|
| Total hospitalizations | 13 | 9 |
| 0 hospitalizations | 80 | 78 |
| 1 hospitalization | 10 | 5 |
| 2 hospitalizations | 1 | 1 |
| 3 hospitalizations | 1 | 3 |
| >3 hospitalizations | 1 | 0 |
| Antibiotics: Day 1 to <Month 3 | 22 | 19 |
| Antibiotics: Month 3 to <Month 6 | 29 | 20 |
| Antibiotics: Month 6 to <Month 9 | 24 | 15 |
| Antibiotics: Month 9 to <Month 12 | 21 | 17 |
| Antibiotics: Month 12 to <Month 15 | 30 | 21 |
| Antibiotics: Month 15 to <Month 18 | 21 | 15 |
| Antibiotics: Month 18 to <Month 21 | 26 | 15 |
| Antibiotics: Month 21 to <Month 24 | 20 | 15 |
| g/L | Zemaira® | Placebo |
|---|---|---|
| TLC | 45.5 ± 15.8 | 48.9 ± 15.5 |
| FRC | 47.6 ± 15.7 | 50.7 ± 15.0 |
Collected over For the duration of the study (25 months; 1 month screening period, 24 months treatment period).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Zemaira® | — | 28/93 (30.1%) | 90/93 (96.8%) |
| Placebo | — | 28/87 (32.2%) | 84/87 (96.6%) |
| Event | Zemaira® | Placebo |
|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 9/93 | 2/87 |
| PneumoniaInfections and infestations | 3/93 | 4/87 |
| Lower respiratory tract infectionInfections and infestations | 1/93 | 4/87 |
| DiverticulitisInfections and infestations | 1/93 | 2/87 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/93 | 2/87 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 2/93 | 1/87 |
| Lung neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/93 | 1/87 |
| BronchitisInfections and infestations | 1/93 | 1/87 |
| AppendicitisInfections and infestations | 0/93 | 1/87 |
| CellulitisInfections and infestations | 0/93 | 1/87 |
| Event | Zemaira® | Placebo |
|---|---|---|
| HeadacheNervous system disorders | 38/93 | 34/87 |
| NasopharyngitisInfections and infestations | 30/93 | 26/87 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 27/93 | 19/87 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 22/93 | 10/87 |
| CoughRespiratory, thoracic and mediastinal disorders | 21/93 | 8/87 |
| Condition aggravatedGeneral disorders | 20/93 | 14/87 |
| Lower respiratory tract infectionInfections and infestations | 18/93 | 17/87 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 16/93 | 8/87 |
| Upper respiratory tract infectionInfections and infestations | 15/93 | 14/87 |
| InfluenzaInfections and infestations | 14/93 | 10/87 |
| Age, Continuous(years) | Zemaira® | Placebo | Total |
|---|---|---|---|
| Mean | 53.81 ± 6.193 | 52.40 ± 7.812 | 53.13 ± 7.374 |
| Sex: Female, Male(Participants) | Zemaira® | Placebo | Total |
|---|---|---|---|
| Female | 45 | 37 | 82 |
| Male | 48 | 50 | 98 |
| Baseline percent predicted forced expiratory volume in 1 second (FEV1)(percentage) | Zemaira® | Placebo | Total |
|---|---|---|---|
| Mean | 47.4 ± 12.1 | 47.2 ± 11.1 | 47.3 ± 11.6 |
| Baseline diffusion capacity of carbon monoxide (DLCO)(mL/min/mmHg) | Zemaira® | Placebo | Total |
|---|---|---|---|
| Mean | 13.6 ± 5.3 | 15.0 ± 5.6 | 14.3 ± 5.5 |
| Number of participants with ZZ genotype (A1-PI deficiency), or SZ, Z / Null or Other genotype(participants) | Zemaira® | Placebo | Total |
|---|---|---|---|
| ZZ | 83 | 83 | 166 |
| SZ | 2 | 0 | 2 |
| Z / Null | 2 | 1 | 3 |
| Other | 6 | 3 | 9 |
The record gives a start of Mar 2006, a primary completion of Sep 2012 and a completion of Sep 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2015, 2 years 4 months after primary completion. A results delay was requested in Oct 2013.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alpha 1-Antitrypsin
alpha 1-Antitrypsin Deficiency →